Boston Scientific (NYSE: BSX) announced new study findings demonstrating the superiority of its Farapulse pulsed field ...

Atrial tachyarrhythmia recurred in 39 patients treated with Boston Scientific’s Farapulse PFA device, while 53 people had recurrence in the Medtronic cryoablation group.

The SINGLE SHOT CHAMPION study increases momentum for PFA as a first-line option for pulmonary vein isolation, say experts.

Abbott is joining the worldwide race to make pulsed field ablation the standard procedure for atrial fibrillation with an ...

Dr. Richardson performed the first PFA procedure at CHI Memorial using the FDA-approved FARAPULSE PFA system. Officials said, "During the PFA procedure, a catheter is inserted into a large vein in ...

Here are the key competitors: Double-digit growth for BSX in electrophysiology (FARAPULSE) and structural heart (WATCHMAN) has recently set it apart. Its operating margin of ~27%, well above that ...

The stock rose during the quarter after the company reported better-than-expected organic growth and raised its earnings guidance, driven by continued strength in FARAPULSE, its atrial ...

Meyer specifically mentions the Watchman FLX, Farapulse and ACURATE Neo2 as key products for investors to watch. In the next few years, Meyer says these products will help Boston Scientific ...

The cardiovascular segment, led by the success of the Farapulse system, grew nearly 29% to $2.94 billion, while the medical-surgical division reported a 12% revenue increase. Looking ahead ...